OCA
ONC icon

Octagon Capital Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Octagon Capital Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,300
Closed -$1.52M – 42
2022
Q3 		$1.52M Buy
+11,300
New +$1.94M 0.26% 31

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Octagon Capital Advisors's ONC Position: Q4 2022 in Review

Octagon Capital Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2022, closing a stake of 11,300 shares — an estimated $1.52M sold.

Octagon Capital Advisors first reported a position in ONC in Q3 2022 and held it in 1 quarter. The position peaked at $1.52M in Q3 2022. 212 funds tracked by Wall St. Rank hold ONC as of Q4 2022.

  • Octagon Capital Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 11,300 BeOne Medicines Ltd shares in Q4 2022, an estimated $1.52M.
  • Octagon Capital Advisors first reported a position in BeOne Medicines Ltd in Q3 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's BeOne Medicines Ltd position peaked at $1.52M in Q3 2022.
  • 212 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.